Maplight Therapeutics Inc (MPLT)

$19.07 +1.05 (5.83%)
Market Cap 817.62M
Revenue (ttm) 0.00
Net Income (ttm) -77.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 188,100
Avg Vol 307,346
Day's Range N/A - N/A
Shares Out 45.37M
Stochastic %K 72%
Beta N/A
Analysts Strong Sell
Price Target $31.00

Company Profile

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's diseas...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 984 6300
Address:
800 Chesapeake Drive, Redwood City, United States
IPOtweet
IPOtweet Jan. 9 at 3:20 PM
Biotech IPOs are back: Why 2026 could mark a hot year for the sector $AKTS $SEPN $LBRJ $MPLT $EVMN $IPO #IPO https://zpr.io/RSKbRHiEVAEU
1 · Reply
JFais
JFais Jan. 8 at 9:26 PM
$MPLT- quite an intriguing if early-stage pipeline at $600M EV @JoseRestonVA
0 · Reply
prismmarketview
prismmarketview Jan. 5 at 5:25 PM
MapLight Therapeutics (Nasdaq: $MPLT) has received FDA Fast Track designation for ML‑007C‑MA, an oral M1/M4 muscarinic agonist in Phase 2 development to treat hallucinations and delusions in Alzheimer’s disease psychosis, with the 300‑patient VISTA trial now enrolling and topline data expected in the second half of 2027. https://prismmarketview.com/maplight-therapeutics-ml-007c-ma-earns-fda-fast-track-designation-for-alzheimers-disease-psychosis/
0 · Reply
Zachary192
Zachary192 Dec. 21 at 7:40 PM
$MPLT
0 · Reply
Zachary192
Zachary192 Dec. 21 at 7:39 PM
$MPLT barely any watchers lol
1 · Reply
prismmarketview
prismmarketview Dec. 16 at 4:41 PM
SandboxAQ teams up with MapLight Therapeutics (Nasdaq: $MPLT) in a deal worth up to $200M to use AI and molecular simulation to discover first-in-class therapies for CNS disorders. https://prismmarketview.com/sandboxaq-and-maplight-therapeutics-partner-to-develop-ai-discovered-first-in-class-cns-therapies/
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 5:11 PM
$MPLT
0 · Reply
Hopipaytrader
Hopipaytrader Dec. 9 at 4:35 AM
$MPLT recent ipo
0 · Reply
FITTEST_RETAIL_TRADER
FITTEST_RETAIL_TRADER Dec. 7 at 9:19 PM
$MPLT I AM ON VANDA BUT THIS CAN GO 300$ %60 INSIDER OWN KEEP YOUR EYES PEELED
0 · Reply
Drewidia
Drewidia Dec. 5 at 11:58 AM
$KULR $MPLT $NKLR $USAR
0 · Reply
Latest News on MPLT
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

Jan 9, 2026, 7:00 AM EST - 3 days ago

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

Jan 5, 2026, 7:00 AM EST - 7 days ago

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

Dec 16, 2025, 7:00 AM EST - 27 days ago

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Dec 4, 2025, 7:00 AM EST - 5 weeks ago

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 29, 2025, 9:06 AM EDT - 2 months ago

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

Oct 27, 2025, 11:48 AM EDT - 2 months ago

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

MapLight Therapeutics Announces Pricing of Initial Public Offering

Oct 26, 2025, 5:30 PM EDT - 2 months ago

MapLight Therapeutics Announces Pricing of Initial Public Offering

US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On

Oct 25, 2025, 5:43 AM EDT - 2 months ago

US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On

AGCC AHMA ARM BGIN IPO IPOS KVUE

MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments

Sep 24, 2025, 2:14 PM EDT - 3 months ago

MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments

MapLight Therapeutics IPO Registration Document (S-1)

Sep 19, 2025, 4:11 PM EDT - 4 months ago

MapLight Therapeutics IPO Registration Document (S-1)

CNS disorder biotech MapLight Therapeutics files for a $100 million IPO

Sep 19, 2025, 6:15 AM EDT - 4 months ago

CNS disorder biotech MapLight Therapeutics files for a $100 million IPO

IPOtweet
IPOtweet Jan. 9 at 3:20 PM
Biotech IPOs are back: Why 2026 could mark a hot year for the sector $AKTS $SEPN $LBRJ $MPLT $EVMN $IPO #IPO https://zpr.io/RSKbRHiEVAEU
1 · Reply
JFais
JFais Jan. 8 at 9:26 PM
$MPLT- quite an intriguing if early-stage pipeline at $600M EV @JoseRestonVA
0 · Reply
prismmarketview
prismmarketview Jan. 5 at 5:25 PM
MapLight Therapeutics (Nasdaq: $MPLT) has received FDA Fast Track designation for ML‑007C‑MA, an oral M1/M4 muscarinic agonist in Phase 2 development to treat hallucinations and delusions in Alzheimer’s disease psychosis, with the 300‑patient VISTA trial now enrolling and topline data expected in the second half of 2027. https://prismmarketview.com/maplight-therapeutics-ml-007c-ma-earns-fda-fast-track-designation-for-alzheimers-disease-psychosis/
0 · Reply
Zachary192
Zachary192 Dec. 21 at 7:40 PM
$MPLT
0 · Reply
Zachary192
Zachary192 Dec. 21 at 7:39 PM
$MPLT barely any watchers lol
1 · Reply
prismmarketview
prismmarketview Dec. 16 at 4:41 PM
SandboxAQ teams up with MapLight Therapeutics (Nasdaq: $MPLT) in a deal worth up to $200M to use AI and molecular simulation to discover first-in-class therapies for CNS disorders. https://prismmarketview.com/sandboxaq-and-maplight-therapeutics-partner-to-develop-ai-discovered-first-in-class-cns-therapies/
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 5:11 PM
$MPLT
0 · Reply
Hopipaytrader
Hopipaytrader Dec. 9 at 4:35 AM
$MPLT recent ipo
0 · Reply
FITTEST_RETAIL_TRADER
FITTEST_RETAIL_TRADER Dec. 7 at 9:19 PM
$MPLT I AM ON VANDA BUT THIS CAN GO 300$ %60 INSIDER OWN KEEP YOUR EYES PEELED
0 · Reply
Drewidia
Drewidia Dec. 5 at 11:58 AM
$KULR $MPLT $NKLR $USAR
0 · Reply
topstockalerts
topstockalerts Dec. 4 at 12:42 AM
Top Gainers PT2 $KXIN $MPLT $KZIA $TLIH $PMAX
1 · Reply
topstockalerts
topstockalerts Dec. 3 at 9:10 PM
Top Gainers PT2 $LFWD $KXIN $MPLT $POET $PMAX
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 8:00 PM
Top Gainers PT2 $QCLS $KXIN $MPLT $AARD $PMAX
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 5:56 PM
Top Gainers $CAPR $IRBT $VRAX $KITT $MPLT
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 4:54 PM
$MPLT It wants to move higher....
0 · Reply
notreload_ai
notreload_ai Dec. 3 at 4:48 PM
$MPLT sees upside as $BMY continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026. https://notreload.xyz/maplight-gains-as-bristol-myers-continues-adept-2-trial/
0 · Reply
stockanalysis_
stockanalysis_ Dec. 3 at 4:45 PM
Gainers Today: $CAPR $IRBT $VRAX $MPLT $KXIN Save this screener: https://stockanalysis.com/markets/gainers/?ref=saveontrading
0 · Reply
topstockalerts
topstockalerts Dec. 3 at 3:57 PM
Top Gainers PT2 $PMAX $SMX $MPLT $CGCTW $AVXL
0 · Reply
Quantumup
Quantumup Dec. 3 at 3:53 PM
Jefferies reiterated $MPLT Buy/$32 KRTX - $BMY CERE - $ABBV $NBIX Jefferies said in its note to investors: In H2:26, we think oral ML-007C-MA (novel M1/M4 muscarinic) has a 30-40% PoS to generate superior Phase II schizophrenia data (pot'l +100% stock move), helping de-risk the second program in Alzheimer's psychosis, which has Phase II data in H2:27 (another pot'l +100% move). Approved in SCZ, BMY's Cobenfy (M1/M4) is delaying its Phase III ADP readout (ADEPT-2) to YE:26 (likely after MPLT's SCZ data), allowing '007 to first prove whether it is superior in SCZ.
0 · Reply
Hopipaytrader
Hopipaytrader Dec. 3 at 2:03 PM
$MPLT 22 watchers 12/3/25 9am
0 · Reply
JarvisFlow
JarvisFlow Nov. 21 at 3:02 PM
Jefferies has updated their rating for MapLight Therapeutics ( $MPLT ) to Buy with a price target of 32.
0 · Reply
JarvisFlow
JarvisFlow Nov. 21 at 3:01 PM
Leerink Partners has updated their rating for MapLight Therapeutics ( $MPLT ) to Outperform with a price target of 30.
0 · Reply